In this week’s episode, host Mike Moore speaks with Omar Khateeb, Founder and CEO of Khateeb & Co., and creator of the game-changing Medical Sales Network Effects Program course.Social media can be a powerful tool for influencing buyers in the medical industry, and Omar’s course is designed to help people in the industry capitalize on that. How do you capture and sustain attention? And how do you channel that attention into something?Today, Mike and Omar talk more about why the course was created, gaining persuasive leverage over competitors, driving product adoption, and the value of a strong social media presence.Notable Quotes“People who are in employment, you're essentially trading your time for money and you're somewhat of a slave, right? And if you have not been using LinkedIn at all, nobody knows you, nobody knows your name, nobody knows any of these things. Moment that a layoff happens, or let's say you're unhappy, you have no idea where to start. You don't even have an idea of what exists in the world. And so what do you end up doing? Just put your head down and keep grinding out more. Just work harder.” - Omar (21:56)In This Episode(01:34) Mike’s posts going viral since enrolling in Omar’s course(03:24) Taking advantage of the organic reach you can get through LinkedIn(04:46) Omar’s background(10:24) How Omar put 35 deals in the pipeline in 60 days(12:57) What are network effects?(21:07) Gaining persuasive leverage over competitors(23:02) Omar’s CEP framework(25:42) The first step to influencing is getting attention(32:36) If you want to make more money, you can’t do that on your own(37:21) The problem Omar wants to solve with his course(39:45) Omar’s “aha” moment(48:28) What’s in store for people in C-suite who are interested in the course?(55:10) The essence of network effects(57:57) How can people get started in the course?Our GuestOmar Khateeb is the Founder and CEO of Khateeb & Co., which helps medtech companies grow sales and drive product adoption at scale using social media. He is the host of The State of MedTech podcast, and the mind behind the game-changing Medical Sales Network Effects Program.

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health

In this week’s episode, host Mike Moore talks to Anna Lisa Somera, CEO of Rhaeos, and the 1st female winner of MedTech Innovator, the largest medical device competition in the world.With the effect of the COVID-19 pandemic in the medical industry, Rhaeos has responded to the big transition of the care setting with their wireless wearable device, FlowSense – a non-invasive thermal sensor that is set to solve a really big problem in Hydrocephalus management.Today, Mike and Anna Lisa discuss how Rhaeos started out, how FlowSense works and how it addresses the need for Hydrocephalus management.Notable Quotes“I had the fortune of meeting a mom of a hydrocephalus patient and she told me how she couldn't work anymore, how her daughter missed so many days of school, how there've been countless times that she's been to the ER, and how her life is hard. But she, as a mom, and her primary caregiver works hard day and night so that her daughter has a normal life as possible. And as she was telling me her story, I had to think of happy thoughts because I'm a mom of two and I’m like, Anna Lisa, don't cry, just keep it together. I wasn't prepared for that. I can read about it, but then when someone is in front of you telling you how hard their life is and then how what you're working on can help them, that's like a different feeling.” - Anna Lisa (15:27)In This Episode(01:39) How Rhaeos started(06:27) Anna Lisa as Rhaeos’ employee number one(08:21) What makes FlowSense unique and how does it work?(15:18) The moment Anna Lisa realized that Rhaeos was the company for her(17:30) What engineers do in the lab is making a difference and changing lives(20:26) The challenges that Rhaeos faced(24:05) Rhaeos’ experience with the FDA(25:55) The lack of funding on the academic side for hydrocephalus(33:20) The biggest challenge that Rhaeos will face from a commercial perspectiveOur GuestAnna Lisa Somera is the Co-founder and Chief Executive Officer of Rhaeos, Inc. She is an entrepreneur with deep experience in startups, venture capital, technology transfer, biomedical research, and life science consulting. She specializes in early-stage, cutting edge technology businesses and has been a part of the entrepreneurial community for 18 years.

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health

In this week’s episode, host Mike Moore talks to Craig Froude, the CEO and co-founder of healthcare fintech app medZERO, which helps lower healthcare costs for employers and provides higher quality services to employees. Many Americans can’t afford a surprise expense of $400 without going into debt – yet the average family will spend over $3200 in out-of-pocket health costs this year alone. medZERO bridges that gap by giving employees on-demand access to funds to pay their out-of-pocket healthcare expenses over time—at zero interest and with zero fees. Today, Mike and Craig discuss the state of the American healthcare system, Craig’s background at WebMD, how medZERO is helping make healthcare more accessible than ever and more.In This Episode(02:52) Setting the stage for medZERO (05:51) Craig’s background at WebMD, and how he helped found medZERO(10:55) medZERO’s early challenges(17:42) How medZERO works(19:08) Two primary use cases(26:12) How medZERO benefits employers(30:15) medZERO’s development, and where it’s at now(36:13) The biggest challenges facing medZERO as it grows(42:31) How medZERO helps refinance medical debtOur GuestCraig Froude is the CEO of medZERO. Before that, he co-founded a technology-enabled health management company called WellMed. In 2002, WellMed successfully sold to WebMD, where Craig ran WebMD Health Services (WHS) for seven years as Executive Vice President/General Manager before becoming President in 2010.

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health

In this week’s episode, host Mike Moore talks to Dr. Sam Qamar, the Co-Founder, Chief Medical Officer, and former CEO of telehealth technology company MedWand Solutions.MedWand is a remote diagnostic device that helps providers conduct real-time examinations. Roughly the size of a computer mouse, MedWand provides live monitoring, remote clinical-grade vitals capture, and support for external AI-based vitals data analysis – all the tools a clinician needs for a comprehensive virtual exam. Today, Mike and Sam discuss MedWand’s role in the future of telemedicine, how the stark differences between clinical medicine and telehealth paved the way for MedWand’s invention, and the challenges of bringing this revolutionary technology to life. Notable Quotes“In the real world, if you come in with a cough and a fever, you would at least expect me to listen to your lungs, get your temperature, maybe get a pulse, make sure you don't have COVID perhaps – you expect an examination of sorts when you come in. In fact, you would probably think very differently about a doctor who didn't examine you or put their hands on you when you were sick and you would leave the office dissatisfied. Yet in telemedicine, we had shunned and basically ignored this whole critical component. The standard of care is to listen to someone's lungs is to get their temperature, get their vitals, get data. And that wasn't being done. [Telemedicine and clinical medicine] were both operating in parallel. And that bothered me as a doctor, as a futurist. So I decided to do something about it.” – Sam (05:32)In This Episode(02:10) The genesis of MedWand(06:29) Clinical medicine expectations vs telemedicine expectations(10:15) The engineering behind MedWand(15:15) The Swiss Army Knife of telehealth(19:48) “Borderless medicine” (23:53) Star Trek, The Jetsons and modern medicine(25:35) The future of primary care(33:33) How MedWand works(41:50) The road to FDA approval(43:24) Revolutionizing the transition from hospital to home careOur GuestDr. Sam Qamar is the Co-Founder, Chief Medical Officer, and former CEO of MedWand Solutions. Prior to MedWand, Sam founded Direct Primary Care company MedLion and worked with Google to help develop telemedicine technology. He completed his medical training at the University of Pennsylvania, and is a member of the MIT Tech Review Global Panel, AMA, and American Academy of Family Physicians. 

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health

In this week’s episode, host Mike Moore speaks with Stephen Scheeler, the CEO and Managing Director of brain data company Omniscient Neurotechnology. Omniscient uses aritifical intelligence and a new field of neurotechnology called connectomics to create a digital map of the brain, known as a connectome, to better understand and eventually design unique treatments for conditions like depression, Alzheimer’s, schizophrenia and stroke. Today, Stephen talks about how brain mapping works, the science behind connectomics, and the vast human potential Omniscient Neurotechnology is hoping to unlock. Notable Quotes“They said, this changes everything. This changes our understanding of the human brain so fundamentally that it's gonna unlock all kinds of human potential over the next, you know, hundred years. And when you have people with this caliber tell you those things, you take pause. And so we started to talk about how we could maybe work together. I started helping them figure out their business model. I went to China to talk to some of the researchers that were already working in that market. And I got more and more fascinated and just saw the potential of what we were trying to build. So I kind of got more and more involved.” – Stephen (10:35)“Everybody, every wiring, every building is a little different. And so what we do is we bring those wiring maps. We build those maps so that if you have pain or you forgot where you left your keys, or you're feeling a little anxious or depressed or whatever, if you're suicidal, if it's that severe, we can map that. And we can show where in your connectome, in your wiring, the problem lies. And so that's a complete transformation for everything we do about the human brain today.” – Stephen (15:31)In This Episode(01:33) Stephen’s background(04:15) The genesis of Omniscient Neurotechnology(08:45) Neuroscience, AI and the field of connectomics (13:01) What is connectomics? (16:16) Connectomics and mental health treatment(17:31) How brain mapping works(27:10) The economic benefits and human potential of Omniscient Neurotechnology(29:44) Psychedelics and neuroscience(35:26) The surgical implications(48:56) The future of Omniscient(51:30) Omniscient’s biggest challengesOur GuestStephen Scheeler is the CEO and Managing Director of brain data company Omniscient Neurotechnology. Previously, he served as the CEO of Facebook for Australia and New Zealand. Stephen is also the founder of global advisory The Digital CEO, Senior Advisor to McKinsey & Company, and Executive-in-Residence at Asia-Pacific’s leading business school, the Australian Graduate School of Management. He has advised the leaders of Qantas, Suncorp, Telstra, Wesfarmers, AMP, CUB, Brambles, Google, and the Australian Government. Stephen is also a member of the Australian Prime Minister's Knowledge Nation 100 as one of Australia’s top innovation leaders. 

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health

Historically, echo analysis has been too expensive or inaccessible for many heart disease patients to receive the care they need. Today’s guests, James Hare and Dr. Carolyn Lam of Us2.ai, are changing that. Us2 is a decision support tool that uses artificial intelligence to automate reading any DICOM (Digital Imaging and Communications in Medicine), anytime, from any device. It is FDA-cleared, vendor-agnostic, and delivers peer-reviewed results that are shown to be interchangeable with expert human sonographers. Us2’s mission is to give everyone full access to their heart health with easy, mobile echo analysis.Today, James and Dr. Lam discuss why echos can be tricky even for medical experts to get right, how Us2 supports both physician and patient use across a variety of cardiac conditions and the healthcare democratization movement. Notable Quotes“It should be accessible to everybody to look at the heart. Why shouldn't you be able to look at the heart and see you've got a hole in your heart or a part of the heart that's not working well or a valve is not working well? I mean, we should be able to do that everywhere.” – Dr. Carolyn Lam (04:02)“There's a lot of well merited skepticism about new AI technologies and the burden is on us to prove that what we have done is useful and it works. But once we push beyond that, once people actually see it, it's just the best feeling in the world. And the reality is that everybody in this, as skeptical as they are, everyone knows what the future is. It's just a matter of how soon we're gonna get there.” – James Hare (18:37)In This Episode(03:36) Us2’s origins (15:20) How it works(19:40) Use cases and the intricacies of heart failure that Us2 can identify (25:38) Us2 uses beyond heart failure(31:30) Us2’s commercial outlook (33:25) The biggest challenge during Us2’s development(35:13) Finding a shared language across business, medicine and tech(39:05) The future of Us2 in hospitals and physician officesOur GuestsUs2.ai CEO and Co-founder James Hare previously served as the Co-founder and President of eDreams, which IPO’d in 2014 and has become one of the world’s most successful e-commerce sites. Before starting Us2, James worked at organizations including EFI, UbiSoft and Netscape, and earned his MBA from Stanford and BA from Harvard.Dr. Carolyn Lam is the Co-founder & Non-Exec Head of Medical Affairs, and is a tenured Professor at Duke-National University in Singapore, where she founded and continues to run the first Women’s Heart Clinic. Dr. Lam received her Masters from the Mayo Clinic, graduated from the Stanford Executive Program and then earned her PhD from the University Medical Center Groningen in the Netherlands.

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health

In this week’s episode, host Mike Moore talks with MedScout co-founder and CEO Skylar Talley about an innovative, intuitive new platform tailor-made to help life sciences companies go to market and grow at scale. With MedScout, sales teams can easily access everything they need to drive sales. Seamlessly integrated with your CRM, reps can find the latest medical procedural data, optimize territories, uncover deep insights about a physician's practice or facility's operations, and manage prospect lists, all in one place. Today, Skylar shares a live demo of MedScout, its mobile app, the targeting criteria system, pipeline capabilities and more. Notable Quotes“The thinking is that once we understand you're targeting criteria, we're ingesting all this data on a regular basis. And if things like that change, if a new payer comes in, if they get into a new procedural area, eventually we wanna be to the point where we're proactively notifying you about that. And then updating all the systems, according to how you want your sales process instrumented. We want to take that manual work out of something that the rep has to do on a regular basis.” – Skylar (24:27)“We wanted to build something that was gonna help the reps in the field. And then the idea obviously is you can come in, have a great visit with Dr. Silver, take notes really quickly, let's say, follow up Monday, save, and then that's gonna sink down to your CRM and then you don't have to worry about going in and filling out Salesforce or anything whenever you get back to the hotel. …  You're out in the field often. So we felt like this mobile app component was gonna be big and we wanted to get that right from the start and also get it into people's hands and get feedback. Hey, what would be helpful in the app for you? So, yeah, pretty proud of that.” – Skylar (34:45)In This Episode(02:43) How MedScout helps life sciences companies create more effective sales plans(05:14) MedScout’s origins (09:52) “Tactical visibility,” territory modeling, and getting tech to market faster(11:44) The longstanding problems MedScout solves in the medtech space(17:23) The MedScout demo – mobile app, onboarding process, targeting criteria, pipeline and more(26:39) How MedScout works to drive revenue at scale (30:15) Dynamic management of rep teams in-app(36:00) MedScout’s target customers and pricing(40:06) MedScout’s differentiators – built for individual reps, usability and simplicity (43:41) MedScout’s future endeavorsOur GuestSkylar Talley is the co-founder and CEO of MedScout. After earning a degree in finance from UT Austin, Skylar worked at startups including Storable, Waldo Photos, and AlienVault, which was purchased by AT&T and now forms a significant portion of AT&T’s business cybersecurity division. 

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health

In today’s episode, host Mike Moore sits down with Eugene Malinskiy, CEO and co-founder of medtech firm Lazurite, whose cutting-edge ArthroFree™ System is poised to revolutionize surgery both for surgeons and their patients. ArthroFree™ is the world’s first fully wireless, minimally invasive, FDA-approved surgical camera. Its cableless setup means surgeons can work freely, while also simplifying the sterile field and minimizing setup and takedown process. ArthroFree™’s endoscopic visualization system seamlessly integrates into existing OR workflows for more efficient procedures and better patient outcomes. Today, Eugene talks about designing ArthroFree™ with surgeon feedback, the current state of medtech and the future of wireless OR technology.Notable Quotes“The docs have gotten better at doing the procedures, but they're using equipment that was really created and commercialized 30 years ago. … You have cables that are going across the surgical field, across the patient and into the surgeons or the staff's hands. And these cables have always existed. And it's kind of crazy because … there's really been no major change in how these procedures are actually done [in the last 30 years]. And so what we've done is we've created the world's first wireless camera system to try to eliminate and try to start eliminating those cables.”  – Eugene (07:07)“I went around and showed this to surgeons. And they said, ‘Oh my God, you think you could actually solve wireless?’ I'm like, ‘I think I can.’ And they said, ‘That's fantastic. We've been wanting this for the last 10 or 20 years.’ And then I asked them because we've always prided ourselves on taking feedback from our champions, from the surgeons, the nurses, the facilities, the innovators, right. We wanted to make sure we were building something that they want.” – Eugene (35:27)In This Episode(02:01) What ArthroFree™ is and how it works(04:47) The current state of the medical industry, and where ArthroFree™ fits in(22:23) Challenges during ArthroFree™’s development(28:03) The wireless problem(38:37) Procedures ArthroFree™ revolutionizes(43:45) ArthroFree™’s target market(49:36) The importance of physician feedback in ArthroFree™’s developmentOur GuestEugene Malinskiy is the CEO and co-founder of medtech firm Lazurite. Before Lazurite, he served as the CEO and founder of DragonID, a biomedical engineering firm specializing in orthopedic and cardiology devices.Eugene received his MS in Biomedical Engineering from Cleveland State University. In 2015, he was named one of Forbes’ 30 Under 30 in Manufacturing & Industry.

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health

In this episode, host Mike Moore talks with healthcare technology entrepreneur & icon, Amit Vohra about one of his many exciting ventures, neuro42. neuro42 is currently developing the world’s first portable, robotic, AI powered MRI for screening, diagnosis and live image-guided interventions.As the future of imaging, neuro42’s platform is designed to require only minimal setup and is backed by over 30 patents for the most efficient diagnosis and treatment of serious neurological conditions.Today, neuro42 President and CEO Dr. Vohra shares his vision for a future of superior patient care powered by intraoperative robotic guidance and predictive analysis.Notable Quotes“I think that's the exciting part about it, not just creating a new clinical pathway, but also to get a buy-in from all the stakeholders that allowed us to create a product that could be used on patients. And the early clinical data on that side that we are doing is creating an impact in our clinical studies.” – Dr. Vohra (19:42)“In a way [neuro42] is disruptive, but it's not that disruptive that, you know, these [doctors] can't implement it in their workflow. What it does is simplify their workflow as well and create some efficiency there.” – Dr. Vohra (22:26)In This Episode(03:00) What neuro42 does, and how it’s unique to an MRI (11:24) How neuro42 uses robotics to perform hyper-precise procedures(17:20) The biggest challenge during neuro42’s development(23:21) Where neuro42 stands in the regulatory process(28:55) How COVID-19 impacted neuro42’s development(33:42) Dr. Vohra’s origins with neuro42 and Promaxo(36:42) Dr. Vohra’s take on the trend of early commercialization(45:22) neuro42’s company culture, and what Dr. Vohra and his team look for in new hires(49:02) The future of neuro42Our GuestEntrepreneur and business strategist Dr. Amit Vohra leads multiple healthcare technology startups, including MRI and robotics company neuro42, where he serves as President and CEO; medical AR/VR company 8chili Inc, where he is Co-Founder and Director; and MR technology firm Promaxo, where he serves as President, Co-Founder and CEO. Additionally, Dr. Vohra is an advisor to Fanisko, Triocula and UnityDx, and serves on the board at Navaux.

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health

In this week’s episode, host Mike Moore talks with Joel Portice, President and CEO of egnite about its flagship solution, CardioCare.Developed at Edwards Lifesciences, CardioCare is a digital health platform that uses artificial intelligence and big data analytics to help identify and manage patients with severe heart disease.More than 50 hospitals across the country currently use CardioCare to help manage cardiovascular patients, make referrals to CV specialists, standardize quality of care and reduce heart patient mortality. Notable Quotes“There's nothing more intimate than what is gonna happen to us in our healthcare experience. And yet there are so many ways people can fall through the cracks.” – Joel Portice (02:45)“If you have that [severe structural heart disease], your mortality is about 24 months. So for me, what gets me really excited and what CardioCare was really all about was let's find those people that have this severe case of structural heart disease, and let's identify them and let's engage with them and manage them through this clinical care pathway, which as you know, can be daunting. It can be fragmented, it's convoluted. And if we can help bring these folks into this system and navigate them through this process so that they have a successful outcome, that's really meaningful work. And I think that's what gets our team going.” – Joel Portice (16:24)In This Episode(01:44) egnite’s origins and how Joel got involved(04:32) egnite’s vision for its flagship solution, CardioCare(12:17) How CardioCare works(21:46) Using AI to identify at-risk patients(23:06) Regulatory challenges and difficulties(30:20) CardioCare’s buyer and end user(32:24) egnite’s competitors(36:45) The future of egnite(41:05) Why egnite is spelled with an “e” Our GuestFor the last 25 years, Joel Portice has been focused on using technology to solve some of the biggest problems in healthcare. Before coming to egnite, Joel served as the CEO of KEPRO and Intermedix, co-founded companies IPS, Inc. and Enclarity, and was the President of Verisk Health. Joel currently serves as the President and CEO of egnite Health. 

Resources & Links
LinkedIn: Mike Moore
LinkedIn: The Bleeding Edge of Digital Health